TY - JOUR T1 - Long-term High-quality Survival with Single-agent Mifepristone Treatment Despite Advanced Cancer JF - Anticancer Research JO - Anticancer Res SP - 6511 LP - 6513 VL - 36 IS - 12 AU - JEROME H. CHECK AU - DIANE CHECK AU - CARRIE WILSON AU - PATRICE LOFBERG Y1 - 2016/12/01 UR - http://ar.iiarjournals.org/content/36/12/6511.abstract N2 - Case Report: We show long-term high-quality survival following single-agent treatment with a progesterone receptor antagonist in two cases of advanced metastatic cancer. Because no biopsy was performed (patient refused) the exact type of lung cancer was not determined but the majority of oncologists who evaluated the patient thought that the rapid onset and syndrome of inappropriate anti-diuretic hormone was more consistent with small-cell lung cancer. The US Food and Drug Association granted a compassionate-use investigational new drug approval for use of single-agent 200 mg mifepristone orally/day to a moribund woman with never-treated metastatic lung cancer and a male with bilateral renal cell carcinoma who had undergone only a unilateral hemi-nephrectomy. Both had long-term high-quality survival (5 years for the patient with lung cancer with complete remission of all lung lesions, and 12 years for the male patient with kidney cancer). Neither patient had any side-effects from mifepristone therapy. Conclusion: These cases helped influence the US Food and Drug Association in granting an investigator-initiated investigational new drug study on advanced non-small cell lung cancer. ER -